Dupilumab reduces mucus plugging and improves lung function in patients with moderate-to-severe type 2 asthma.
Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, ...
A systematic review reports that monoclonal antibodies and JAK inhibitors can be effective in the treatment and clearance of ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
Abrocinitib was slightly more effective than dupilumab in treating atopic dermatitis, both in White patients and in patients with skin of color.
Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...
Medpage Today on MSN
Regulatory T-Cell Drug Promising for Eczema, With Hint for Asthma as Well
For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Dupixent sBLA accepted for priority review by the US FDA with a target action date of February 28, 2026; if approved, Dupixent would be the first and only medicine indicated specifically for AFRS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback